Nervous System News and Research

Latest Nervous System News and Research

Autifony Therapeutics awarded £2.2 million to progress first-in-class drug for tinnitus into Phase IIa study

Autifony Therapeutics awarded £2.2 million to progress first-in-class drug for tinnitus into Phase IIa study

Vanda’s HETLIOZ MAA for Non-24-Hour Sleep-Wake Disorder accepted for evaluation by the EMA

Vanda’s HETLIOZ MAA for Non-24-Hour Sleep-Wake Disorder accepted for evaluation by the EMA

P2Y12 and blood clotting: an interview with Dr. Jacobson, NIH

P2Y12 and blood clotting: an interview with Dr. Jacobson, NIH

Alkermes initiates second ALKS 3831 Phase 2 clinical study for treatment of schizophrenia

Alkermes initiates second ALKS 3831 Phase 2 clinical study for treatment of schizophrenia

Individuals who speak more languages may slow down cognitive decline from aging

Individuals who speak more languages may slow down cognitive decline from aging

Ezyme used as target for antidepressants may also provide way to cure prostate cancer

Ezyme used as target for antidepressants may also provide way to cure prostate cancer

HCV reactivation may not worsen survival outcomes for lymphoma patients with HIV

HCV reactivation may not worsen survival outcomes for lymphoma patients with HIV

Forest publishes data from pivotal Phase III Study of Investigational FDC of nebivolol and valsartan

Forest publishes data from pivotal Phase III Study of Investigational FDC of nebivolol and valsartan

ASCO: DelMar presents interim data from VAL-083 clinical trial in refractory GBM

ASCO: DelMar presents interim data from VAL-083 clinical trial in refractory GBM

Patients with AIDS-related lymphomas may face increased risk of CNSi

Patients with AIDS-related lymphomas may face increased risk of CNSi

FDA grants Angiochem’s ANG1005 fast track and orphan drug designation for treatment of glioblastoma multiforme

FDA grants Angiochem’s ANG1005 fast track and orphan drug designation for treatment of glioblastoma multiforme

Newron Pharmaceuticals submits safinamide NDA to FDA

Newron Pharmaceuticals submits safinamide NDA to FDA

Lyme disease bacteria older than human race, says study

Lyme disease bacteria older than human race, says study

Researchers use patterned visual stimulation to control rapid re-wiring of nerve circuits

Researchers use patterned visual stimulation to control rapid re-wiring of nerve circuits

People with high levels of cynical distrust more likely to develop dementia, says study

People with high levels of cynical distrust more likely to develop dementia, says study

Stem cells in outer blood vessel wall appear to involve in brain reaction following stroke

Stem cells in outer blood vessel wall appear to involve in brain reaction following stroke

Study suggests that stiff arteries alone enough to cause high BP in "virtual human"

Study suggests that stiff arteries alone enough to cause high BP in "virtual human"

Norwegian scientists win 2014 Körber prize for their research on grid activity

Norwegian scientists win 2014 Körber prize for their research on grid activity

International partnership of charities funds first immunotherapy clinical trial for children with neuroblastoma

International partnership of charities funds first immunotherapy clinical trial for children with neuroblastoma

Professor receives grant to study stress-induced hypertension, its effects on neuroimmune system

Professor receives grant to study stress-induced hypertension, its effects on neuroimmune system

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.